IDEAS home Printed from https://ideas.repec.org/a/spr/drugsa/v45y2022i5d10.1007_s40264-022-01159-2.html
   My bibliography  Save this article

Supervised Machine Learning-Based Decision Support for Signal Validation Classification

Author

Listed:
  • Muhammad Imran

    (Bayer AG, Digital Transformation and Information Technology Pharma, Decision Science and Advanced Analytics for Medical Affairs, Pharmacovigilance and Regulatory Affairs)

  • Aasia Bhatti

    (Bayer US LLC, Pharmaceuticals, Pharmacovigilance, Benefit-Risk Management TA Radiology)

  • David M. King

    (Bayer US LLC, Digital Transformation and Information Technology Pharma, Adverse Event Management)

  • Magnus Lerch

    (Lenolution GmbH)

  • Jürgen Dietrich

    (Bayer AG, Pharmaceuticals, Pharmacovigilance, Innovation and Digitalization)

  • Guy Doron

    (Bayer AG, Pharmaceuticals, Pharmacovigilance, R&D, Data Sciences)

  • Katrin Manlik

    (Bayer AG, Pharmaceuticals, Pharmacovigilance, Data Science and Insight Generation)

Abstract

Introduction Signal validation in pharmacovigilance is the process of evaluating data to decide whether evidence is sufficient to justify further assessment of a detected signal. During the signal validation process, safety experts in our organization are required to review signals of disproportionate reporting (SDRs) and classify them into one of six predefined categories. Objective This experiment explored the extent to which predictive machine learning (ML) models can support the decision making of safety experts by accurately identifying the most appropriate predefined signal validation category. Methods We extracted cumulative data for six medicinal products, consisting of historic SDR validations and Individual Case Safety Reports, from the company’s safety database for training and testing of the ML model. We implemented a decision tree-based supervised multiclass classifier model termed Gradient Boosted Trees followed by a SHapley Additive exPlanations (SHAP) analysis to mitigate the “black box” effect of the ensemble model by identifying the key predicting features in the model. Following a retrospective analysis, a prospective experiment was conducted to test the model accuracy and user acceptance in a real-life setting. Results The prediction accuracy of our ML model ranged from 83 to 86% over 3 months for the six medicinal products. The applicability of the model was confirmed by the company’s safety experts. Additionally, the systematic predictions provided valuable information to the safety experts and assisted them in reviewing the SDRs efficiently and consistently. Conclusions This experiment demonstrated that it is possible to train a multiclass classification model to accurately predict signal validation categories for SDRs. More importantly, the transparency of the predictions provided by the SHAP analysis led to high acceptance by the safety experts.

Suggested Citation

  • Muhammad Imran & Aasia Bhatti & David M. King & Magnus Lerch & Jürgen Dietrich & Guy Doron & Katrin Manlik, 2022. "Supervised Machine Learning-Based Decision Support for Signal Validation Classification," Drug Safety, Springer, vol. 45(5), pages 583-596, May.
  • Handle: RePEc:spr:drugsa:v:45:y:2022:i:5:d:10.1007_s40264-022-01159-2
    DOI: 10.1007/s40264-022-01159-2
    as

    Download full text from publisher

    File URL: http://link.springer.com/10.1007/s40264-022-01159-2
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.

    File URL: https://libkey.io/10.1007/s40264-022-01159-2?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:drugsa:v:45:y:2022:i:5:d:10.1007_s40264-022-01159-2. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com/economics/journal/40264 .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.